Glycosphingolipids and drug resistance
- PMID: 17010304
- DOI: 10.1016/j.bbamem.2006.08.012
Glycosphingolipids and drug resistance
Abstract
Drug resistance, an all too frequent characteristic of cancer, represents a serious barrier to successful treatment. Although many resistance mechanisms have been described, those that involve membrane-resident proteins belonging to the ABC (ATP binding cassette) transporter superfamily are of particular interest. In addition to cancer, the ABC transporter proteins are active in diseases such as malaria and leishmaniasis. A recent renaissance in lipid metabolism, specifically ceramide and sphingolipids, has fueled research and provided insight into the role of glycosphingolipids in multidrug resistance. This article reviews current knowledge on ceramide, glucosylceramide synthase and cerebrosides, and the relationship of these lipids to cellular response to anticancer agents.
Similar articles
-
Sphingolipid metabolism and drug resistance in hematological malignancies.Anticancer Agents Med Chem. 2011 Nov;11(9):891-903. doi: 10.2174/187152011797655069. Anticancer Agents Med Chem. 2011. PMID: 21707483 Review.
-
Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains.J Lipid Res. 2005 Nov;46(11):2367-76. doi: 10.1194/jlr.M500070-JLR200. Epub 2005 Sep 8. J Lipid Res. 2005. PMID: 16150833
-
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37. doi: 10.1016/j.taap.2004.10.012. Toxicol Appl Pharmacol. 2005. PMID: 15845415 Review.
-
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.Cancer Lett. 2016 Jan 1;370(1):153-64. doi: 10.1016/j.canlet.2015.10.010. Epub 2015 Oct 20. Cancer Lett. 2016. PMID: 26499806 Review.
-
[Drug resistance mediated by ABC transporters].Gan To Kagaku Ryoho. 2004 Jan;31(1):1-6. Gan To Kagaku Ryoho. 2004. PMID: 14750312 Review. Japanese.
Cited by
-
Gaucher's disease and cancer: a sphingolipid perspective.Crit Rev Oncog. 2013;18(3):221-34. doi: 10.1615/critrevoncog.2013005814. Crit Rev Oncog. 2013. PMID: 23510065 Free PMC article. Review.
-
Liver involvement in patients with Gaucher disease types I and III.Mol Genet Metab Rep. 2020 Jan 7;22:100564. doi: 10.1016/j.ymgmr.2019.100564. eCollection 2020 Mar. Mol Genet Metab Rep. 2020. PMID: 32099816 Free PMC article.
-
An atlas of human metabolism.Sci Signal. 2020 Mar 24;13(624):eaaz1482. doi: 10.1126/scisignal.aaz1482. Sci Signal. 2020. PMID: 32209698 Free PMC article.
-
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.Nat Commun. 2024 Aug 14;15(1):6970. doi: 10.1038/s41467-024-51495-3. Nat Commun. 2024. PMID: 39138212 Free PMC article. Clinical Trial.
-
Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.Int J Pharm. 2010 Nov 15;400(1-2):251-9. doi: 10.1016/j.ijpharm.2010.08.044. Epub 2010 Sep 15. Int J Pharm. 2010. PMID: 20816930 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources